Initial data presented from the Investigator Initiated Trial (IIT) at Radboud University Medical Center using the CLS TRANBERG[®] system

Lund, Sweden April 11, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that for the first-time clinical data has been presented from the investigator-initiated study at Radboud University Medical Center in Nijmegen, the Netherlands, on the use of CLS’s MR-guided TRANBERG® system for Focal Laser Ablation (FLA) of localized prostate cancer.

During the ECR (European Congress of Radiology) annual meeting in Vienna, Austria, an abstract by the principal investigator for the ongoing study at Radboud University Medical Center (RUMC), Prof. Jurgen Fütterer and his team was presented “MRI-guided transrectal focal laser ablation for localized low and intermediate risk prostate cancer”. The presentation covered initial experiences and data from the first ten patients in the ongoing trial at RUMC.

The aim of the study is to investigate the feasibility and safety of the TRANBERG® MR-guided system using MR thermometry by Thermoguide™ for accurate ablation control. By use of this system more precise tissue ablation, without damaging vital adjacent structures, is expected. As stated in the abstract the initial experiences support this hypothesis as the data indicates good oncological response and potential improvement in urinary and sexual function.

Recruitment and follow up of the study that was initiated in February 2022 are still ongoing. The study was extended in September 2023 with further five patients, in addition to the ten patients that was already treated.

Link to the abstract on the ECT website: IR in the management of benign and malignant disease in male patients - ESR Connect (myesr.org)

For further information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se